Physician profile
Robert H Lustig
NPI 1457394652
$1,287.94
in general payments reported to CMS, 2019-2025
17 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.70 · 2021: $40.99 · 2022: $119 · 2023: $132 · 2024: $215 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $335.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $279.89 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $97.64 | 2022-2025 | |
| Exact Sciences Corporation | $97.32 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $71.93 | 2024-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $63.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.81 | 2022-2025 | Xifaxan |
| Depuy Synthes Sales INC. | $56.71 | 2025 | Orthovisc, Monovisc |
| Lilly USA, LLC | $55.69 | 2023-2024 | Zepbound, Mounjaro |
| Abbott Laboratories | $36.00 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Braintree Laboratories, INC. | $30.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.76 | 2025 | |
| Medtronic, INC. | $20.92 | 2024 | Endoflip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2025 | Jardiance |
| Abbvie INC. | $17.33 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $14.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.